Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 8/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6434986 | 0.87 | P4HTM (0.62) | P4HTMKDM4EALDH1A1L3MBTL1MEN1 | |
| Hydrochloric Acid SCHEMBL11633575 | 0.86 | P4HTM (0.61) | P4HTMKDM4EALDH1A1L3MBTL1MEN1 | |
| SCHEMBL11632031 | 0.84 | P4HTM (0.59) | P4HTMKDM4EALDH1A1L3MBTL1MEN1 | |
| SCHEMBL11631216 | 0.84 | P4HTM (0.59) | P4HTMKDM4EALDH1A1L3MBTL1MEN1 | |
| SCHEMBL754198 | 0.84 | P4HTM (0.63) | P4HTMKDM4EALDH1A1L3MBTL1MEN1 | |
| Hydrochloric Acid SCHEMBL11633386 | 0.83 | P4HTM (0.57) | P4HTMKDM4EALDH1A1L3MBTL1MEN1 | |
| SCHEMBL11632812 | 0.81 | P4HTM (0.56) | P4HTMKDM4EALDH1A1L3MBTL1MEN1 | |
| SCHEMBL11632984 | 0.80 | MAPK1 (0.54) | P4HTMKDM4EALDH1A1L3MBTL1MAPT | |
| SCHEMBL11630361 | 0.80 | P4HTM (0.55) | P4HTMKDM4EALDH1A1L3MBTL1MEN1 | |
| SCHEMBL11632125 | 0.79 | P4HTM (0.56) | P4HTMKDM4EALDH1A1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4109000-A | HYPOTENSIVES | NIPPON SHINYAKU CO., LTD. (JP) | 1978-08-22 | — | — | US | claimed |
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-20250152601-A1 | Compositions and Methods for the Treatment of Sexual Dysfunctions | THE JONATHAN HURT LIVING TRUST (US) | 2025-05-15 | — | — | US | disclosed |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | NUVAMID SA (CH) | 2024-12-19 | — | — | US | disclosed |
| US-20240116971-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2024-04-11 | — | — | US | disclosed |
| WO-2022223612-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES | NUVAMID SA (CH) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022223613-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2022-10-27 | — | — | WO | disclosed |
| EP-4079310-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES | Nuvamid SA (CH) | 2022-10-26 | — | — | EP | disclosed |
| EP-4079311-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | Nuvamid SA (CH) | 2022-10-26 | — | — | EP | disclosed |
| US-11383084-B2 | Treatment of dermatological conditions via neuromodulation | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| EP-0926137-B1 | Picolin acid derivatives useful in the treatment of IL-1 and TNF mediated diseases | PFIZER (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6416979-B1 | MARASMIELLUS CULTURE PRODUCT; ANTIINFLAMMATORY AGENT, ANTIARTHRITIC AGENTS | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| US-6194442-B1 | ANTIINFLAMMATORY AGENT | PFIZER INC | 2001-02-27 | — | — | US | disclosed |
| US-6034107-A | RHEUMATIC DISORDERS, ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0926137-A1 | Picolin acid derivatives useful in the treatment of IL-1 and TNF mediated diseases | PFIZER INC. (US) | 1999-06-30 | — | — | EP | disclosed |
| US-4109000-A | HYPOTENSIVES | NIPPON SHINYAKU CO., LTD. (JP) | 1978-08-22 | — | — | US | disclosed |
| US-4109000-A | HYPOTENSIVES | NIPPON SHINYAKU CO., LTD. (JP) | 1978-08-22 | — | — | US | disclosed |
| US-4009077-A | Process for the preparation of phenopicolinic acid | NIPPON SHINYAKU CO., LTD. (JA) | 1977-02-22 | — | — | US | disclosed |
| US-4009077-A | Process for the preparation of phenopicolinic acid | NIPPON SHINYAKU CO., LTD. (JA) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116971-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | SNCA, NLN, PARK7 | P4HTM 3412/4885KDM4E 4190/4885ALDH1A1 1523/4885 |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | SNCA, NLN, PARK7 | P4HTM 3599/4885KDM4E 4813/4885ALDH1A1 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.